Banking

Charles River Labs Joins Elite List Of Stocks With 95-Plus Composite Rating

Charles River Labs is benefiting from exposure to a couple of hot markets. It’s a leading animal research tools provider. And the company says it provided support for fully 80% of drugs approved by the FDA in the past five years. On Wednesday, the IBD SmartSelect Composite Rating for Charles River Labs International (CRL) rose to a near-perfect 96.




X



The new score indicates the Wilmington, Mass.-based company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Charles River Labs Profit Growth Ranks High

The stock earns a 90 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 90% of all stocks.

Its Accumulation/Distribution Rating of A, on an A+ to E scale, shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.


See How IBD Helps You Make More Money In Stocks


The company posted a 38% rise in earnings for Q1, to $2.53. Top line growth climbed 17% to $824.6 million, up from 14% in the prior report. The company has now posted accelerating growth in each of the last three quarters.

Charles River Labs International earns the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. qvia Holdings (IQV) is the top-ranked stock within the group.

Charles River Labs International is now out of buy range after breaking out from a 303.89 buy point in a flat base. See if it can provide a new buy opportunity such as a three-weeks-tight base or a rebound off its 50-day or 10-week line.

YOU MIGHT ALSO LIKE:

Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button